ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1697

Are Patients With Rheumatoid Arthritis Still At An Increased Risk Of Tuberculosis and What Is The Role Of Biological Treatment?

Elizabeth V. Arkema1, Jerker Jonsson2, Eva Baecklund3, Maud Rutting4, Judith Bruchfeld5, Nils Feltelius4 and Johan Askling1,6, 1Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2Swedish Institute for Communicable Disease Control, Solna, Sweden, 3Department of Medical Sciences, Rheumatology, Uppsala University Hospital, Uppsala, Sweden, 4Swedish Medical Products Agency, Uppsala, Sweden, 5Department of Medicine, Infectious Diseases Unit, Karolinska Institutet, Stockholm, Sweden, 6Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: anti-TNF therapy, Biologic drugs, rheumatoid arthritis (RA) and tuberculosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Epidemiology and Health Services Research II: Epidemiology in Systemic Lupus Erythematosus and Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose:   Anti-TNF therapy is a risk factor for clinical tuberculosis (TB), which has led to pre-treatment screening and increased vigilance. The extent to which these measures have reduced or removed the TB risk – with or without biological treatment – and how such risks differ between individual biologics remains less clear. We therefore sought to estimate the risk of TB in patients with rheumatoid arthritis (RA) 2002-2011 with and without exposure to biological therapy and to directly compare the risks between biological therapies.

Methods: Data from the Swedish National Population Registers, TB Register and the Swedish Biologics Register were used to conduct a prospective population-based national cohort study (2002-2011). We estimated the rate of TB in the general population (N=173,333), in a cohort of patients diagnosed with RA unexposed to biological therapy (N=37,770) and in a cohort of patients with RA exposed to biologicals (abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, N=10,803). Cox models adjusting for age, sex, country of birth, education, history of diabetes, chronic obstructive pulmonary disease and cancer were used to estimate hazard ratios and 95% confidence intervals (HR; 95%CI). We estimated the risk of TB in the biological-exposed RA population compared to the unexposed, with particular attention to risks by calendar and follow-up time, and risks associated with individual biologics.

Results: Compared to the general population, RA patients not exposed to biologicals had a 4-fold increased risk of TB (HR 4.4 (95%CI 2.7, 7.1) 30 RA, 37 general population TB cases). We identified 19 TB cases with RA who were exposed to a biological before TB diagnosis (etanercept, infliximab, adalimumab or rituximab). The rate of TB in the biological-exposed RA population has decreased since 2002. Individuals with RA who were exposed to any biological had a multivariable-adjusted HR of 4.7 (95%CI 2.5, 9.0) compared to biological-naïve patients. The HR comparing etanercept-exposed patients to biological-naïve was 1.8 (95%CI 0.5, 6.4). The HRs for adalimumab and infliximab compared to etanercept were 3.8 (95%CI 1.0, 14.8) and 2.6 (95%CI 0.6, 11.0) respectively. One case was exposed to rituximab (HR 0.9 95%CI 0.1, 10.6).

Conclusion: The risk of TB in patients with RA is increased compared to the general population. In the past decade, the risk of TB has decreased possibly due to the introduction of pre-treatment screening but remains higher than in RA patients unexposed to biologicals. Between drug comparisons showed that the lowest risk is among those exposed etanercept, but etanercept still carries an increased risk compared to biological-unexposed. The majority of cases observed over the 10 years of follow-up occurred in biological-naïve RA patients.

 

Table. Incidence rates and hazard ratios of tuberculosis comparing biological-naïve to biological-exposed patients with RA, overall and stratified by calendar year of follow-up and total follow-up time.

 

Biological-Naive RA

Biological-Exposed RA

Hazard Ratio* (95% CI)

Overall

 

 

 

TB Cases/Person-years (py)

30/219,571

19/48,337

Overall IR, per 100,000 py (95% CI)

13.7 (9.6, 19.6)

39.3 (25.1, 61.6)

4.7 (2.5, 9.0)

IR (95% CI) by Calendar Year

2002-2006

16.8 (10.3, 27.5)

60.5 (32.6, 112.5)

9.5 (3.9, 22.9)

2007-2011

12.6 (7.5, 21.4)

21.0 (10.9, 40.3)

2.5 (1.0, 6.2)

IR (95% CI) by Follow-up Time

<5 y

14.4 (9.3, 22.3)

48.3 (30.0, 77.7)

7.0 (3.4, 14.5)

≥5 y

15.0 (8.1, 27.9)

8.2 (2.0, 32.8)

1.4 (0.3, 7.1)

Drug-Specific Analysis

Etanercept † IR (95% CI)

15.8 (5.1, 48.9)

1.0 (ref)

Infliximab † IR (95% CI)

67.2 (33.6, 134.4)

2.6 (0.6, 11.0)

Adalimumab † IR (95% CI)

61.1 (29.2, 128.3)

3.8 (1.0, 14.8)

Rituximab † IR (95% CI)

29.0 (4.1, 206.0)

0.9 (0.1, 10.6)

*Comparing biological-exposed to biological-naïve, Adjusted for age, sex, country of birth, education, cancer, diabetes, copd. In drug-specific analysis, comparing each drug to etanercept exposure.

† Exposure from date of initiation until start of next biologic.

RA Rheumatoid Arthritis; TB Tuberculosis; IR Incidence Rate; CI Confidence Interval; PY Person Years; HR Hazard Ratio;

 


Disclosure:

E. V. Arkema,
None;

J. Jonsson,
None;

E. Baecklund,
None;

M. Rutting,
None;

J. Bruchfeld,
None;

N. Feltelius,
None;

J. Askling,

Pfizer Inc,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-patients-with-rheumatoid-arthritis-still-at-an-increased-risk-of-tuberculosis-and-what-is-the-role-of-biological-treatment/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology